{"id":65981,"date":"2023-09-27T09:20:05","date_gmt":"2023-09-27T13:20:05","guid":{"rendered":"https:\/\/ifintechworld.com\/markets\/will-bristol-myers-squibb-stock-rebound-to-its-pre-inflation-shock-level-of-80\/"},"modified":"2023-09-27T09:20:08","modified_gmt":"2023-09-27T13:20:08","slug":"will-bristol-myers-squibb-stock-rebound-to-its-pre-inflation-shock-level-of-80","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=65981","title":{"rendered":"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80?"},"content":{"rendered":"<div>\n<p><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/\">Bristol Myers Squibb stock<\/strong> (NYSE: BMY) currently trades at $59 per share, 6% below the level seen in March 2021, and it has room for growth, in our view. BMY stock was trading at around $77 in early June 2022, just before the Fed started increasing rates, and is now 23% above that level, compared to 14% gains for the S&amp;P 500 during this period. The decline in the stock over recent months can partly be attributed to declining sales of its top selling drug &#8211; Revlimid &#8211; amid biosimilar competition.<\/p>\n<p>Interestingly, BMY stock has had a Sharpe Ratio of <strong>0.1<\/strong> since early 2017, lower than <strong>0.6<\/strong> for the S&amp;P 500 Index over the same period. This compares with the <strong>Sharpe of 1.3<\/strong> for the Trefis Reinforced Value portfolio. Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.<\/p>\n<p>Returning to the pre-inflation shock level of over $80 means that BMY stock will have to gain more than 35% from here, and we think it will likely materialize over time. We estimate <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/no-login-required\/kUG2yRm8\/Bristol-Myers-Squibb-BMY-Valuation-Is-BMY-Stock-Expensive-Or-Cheap-?fromforbesandarticle=trefis230927\">Bristol Myers Squibb\u2019s valuation<\/strong> to be around $76 per share, over 25% above its current market price.<\/p>\n<p>Our detailed analysis of <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/no-login-required\/G74bgQzS\/Bristol-Myers-Squibb-During-2008-Recession-vs-2022-Inflation-Shock-BMY-Stock-Has-35-Upside-If-It-Recovers-To-Pre-Inflation-Shock-Levels-?fromforbesandarticle=trefis230927\">Bristol Myers Squibb\u2019s upside post-inflation shock<\/strong> captures trends in the company\u2019s stock during the turbulent market conditions seen over 2022. It compares these trends to the stock\u2019s performance during the 2008 recession.<\/p>\n<p><fbs-ad position=\"inread\" progressive=\"\" ad-id=\"article-0-inread\" aria-hidden=\"true\" role=\"presentation\"><\/fbs-ad><\/p>\n<p><strong>2022 Inflation Shock<\/strong><\/p>\n<p>Timeline of Inflation Shock So Far:<\/p>\n<ul>\n<li>2020 \u2013 early 2021: Increase in money supply to cushion the impact of lockdowns led to high demand for goods; producers unable to match up.<\/li>\n<li>Early 2021: Shipping snarls and worker shortages from the coronavirus pandemic continue to hurt supply.<\/li>\n<li>April 2021: Inflation rates cross 4% and increase rapidly.<\/li>\n<li>Early 2022: Energy and food prices spike due to the Russian invasion of Ukraine. Fed begins its rate hike process.<\/li>\n<li>June 2022: Inflation levels peak at 9% \u2013 the highest level in 40 years. The S&amp;P 500 index declined more than 20% from peak levels.<\/li>\n<li>July \u2013 September 2022: Fed hikes interest rates aggressively \u2013 resulting in an initial recovery in the S&amp;P 500 followed by another sharp decline.<\/li>\n<li>October 2022 \u2013 July 2023: Fed continues rate hike process; improving market sentiments helps S&amp;P500 recoup some of its losses.<\/li>\n<li>Since August 2023: Fed keeps interest rates unchanged to quell fears of a recession, although another rate hike remains in the cards.<\/li>\n<\/ul>\n<p>In contrast, here\u2019s how BMY stock and the broader market performed during the 2007\/2008 crisis.<\/p>\n<p><strong>Timeline of 2007-08 Crisis<\/strong><\/p>\n<ul>\n<li>10\/1\/2007: Approximate pre-crisis peak in S&amp;P 500 index<\/li>\n<li>9\/1\/2008 \u2013 10\/1\/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9\/15\/08)<\/li>\n<li>3\/1\/2009: Approximate bottoming out of S&amp;P 500 index<\/li>\n<li>12\/31\/2009: Initial recovery to levels before accelerated decline (around 9\/1\/2008)<\/li>\n<\/ul>\n<p><strong>Bristol Myers Squibb<br \/>\n  <fbs-ticker data-name=\"BMY\" data-href=\"https:\/\/www.forbes.com\/companies\/bristol-myers-squibb\" data-type=\"stock\"><br \/>\n   BMY<br \/>\n  <\/fbs-ticker> and S&amp;P 500 Performance During 2007-08 Crisis<\/strong><\/p>\n<p>BMY stock declined from nearly $29 in September 2007 (pre-crisis peak) to $18 in March 2009 (as the markets bottomed out), implying it lost almost 37% of its pre-crisis value. It recovered post the 2008 crisis to levels of around $25 in early 2010, rising 37% between March 2009 and January 2010. The S&amp;P 500 Index saw a decline of 51%, falling from levels of 1,540 in September 2007 to 757 in March 2009. It then rallied 48% between March 2009 and January 2010 to reach levels of 1,124.<\/p>\n<p><strong>Bristol Myers Squibb\u2019s Fundamentals Over Recent Years<\/strong><\/p>\n<p><strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/no-login-required\/fdvQTKX9\/Bristol-Myers-Squibb-Revenue?fromforbesandarticle=trefis230927\">Bristol Myers Squibb\u2019s revenue<\/strong> increased from $26 billion in 2019 to $46 billion in 2022, partly aided by its Celgene<fbs-ticker data-name=\"CELG\" data-href=\"https:\/\/www.forbes.com\/companies\/celgene\" data-type=\"stock\"><br \/>\n  CELG<br \/>\n <\/fbs-ticker> acquisition in 2019. Market share gains for some of its drugs, including its anticoagulant \u2013 Eliquis &#8211; have also bolstered the top-line growth. However, the company now faces biosimilar competition for its top-selling drug \u2013 Revlimid &#8211; which saw its sales fall 22% y-o-y to $10 billion in 2022. The company expects the drug to garner only $5.5 billion in 2023.<\/p>\n<p>Bristol Myers Squibb\u2019s operating margin declined from <strong>23%<\/strong> in 2019 to <strong>18%<\/strong> in 2022. Our <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/no-login-required\/RUrivPcZ\/Bristol-Myers-Squibb-BMY-Operating-Income-Comparison?fromforbesandarticle=trefis230927\">Bristol Myers Squibb Operating Income Comparison<\/strong> dashboard has more details. The company\u2019s earnings stood at $2.97 on a per-share and reported basis in 2022, compared to the $2.02 figure in 2019.<\/p>\n<p><strong>Does Bristol Myers Squibb Have A Sufficient Cash Cushion To Meet Its Obligations Through The Ongoing Inflation Shock?<\/strong><\/p>\n<p>Bristol Myers Squibb\u2019s total debt decreased from $47 billion in 2019 to $39 billion in 2022, while its cash has decreased from $16 billion to around $9 billion over the same period. The company also garnered $13 billion in cash flows from operations in 2022. Bristol Myers Squibb has high debt levels, but with its cash cushion, it is in a good position to meet its near-term obligations.<\/p>\n<p><strong>Conclusion<\/strong><\/p>\n<p>With the Fed\u2019s efforts to tame runaway inflation rates helping market sentiment, we believe BMY stock has the potential for more gains once fears of a potential recession are allayed. That said, unfavorable macroeconomic factors and declining Revimid sales are potential risk factors for realizing these gains.<\/p>\n<p>While BMY stock can see higher levels, it is helpful to see how <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/companies\/BMY\/topic\/peer-comparisons\">Bristol Myers Squibb\u2019s Peers<\/strong> fare on metrics that matter. You will find other valuable comparisons for companies across industries at <strong data-ga-track=\"ExternalLink:https:\/\/www.trefis.com\/data\/topic\/peer-comparisons\">Peer Comparisons<\/strong><strong>.<\/strong><\/p>\n<p>Invest with <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/companies\/PORTFOLIOS\/no-login-required\/M7MacZNG?fromforbes\">Market Beating Portfolios<\/strong><\/p>\n<p>See all <strong>Trefis <\/strong><strong data-ga-track=\"ExternalLink:https:\/\/dashboards.trefis.com\/data\/price-estimates?fromforbes\">Price Estimates<\/strong><\/p>\n<\/div>\n<p>Read the full article <a href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2023\/09\/27\/will-bristol-myers-squibb-stock-rebound-to-its-pre-inflation-shock-level-of-80\/\" target=\"_blank\" rel=\"noopener\">here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol Myers Squibb stock (NYSE: BMY) currently trades at $59 per share, 6% below the level seen in March 2021, and it has room for growth, in our view. BMY stock was trading at around $77 in early June 2022, just before the Fed started increasing rates, and is now 23% above that level, compared [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":65982,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[241],"tags":[83],"class_list":["post-65981","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-featured"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80? | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Bristol Myers Squibb stock (NYSE: BMY) currently trades at $59 per share, 6% below the level seen in March 2021, and it has room for growth, in our view.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=65981\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80? | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Bristol Myers Squibb stock (NYSE: BMY) currently trades at $59 per share, 6% below the level seen in March 2021, and it has room for growth, in our view.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=65981\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-27T13:20:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-27T13:20:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/09\/1695820806_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=65981#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=65981\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80?\",\"datePublished\":\"2023-09-27T13:20:05+00:00\",\"dateModified\":\"2023-09-27T13:20:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=65981\"},\"wordCount\":821,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=65981#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=65981\",\"url\":\"https:\/\/ifintechworld.com\/?p=65981\",\"name\":\"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80? | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-09-27T13:20:05+00:00\",\"dateModified\":\"2023-09-27T13:20:08+00:00\",\"description\":\"Bristol Myers Squibb stock (NYSE: BMY) currently trades at $59 per share, 6% below the level seen in March 2021, and it has room for growth, in our view.\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=65981#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=65981\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=65981#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80? | iFintechWorld","description":"Bristol Myers Squibb stock (NYSE: BMY) currently trades at $59 per share, 6% below the level seen in March 2021, and it has room for growth, in our view.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=65981","og_locale":"en_US","og_type":"article","og_title":"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80? | iFintechWorld","og_description":"Bristol Myers Squibb stock (NYSE: BMY) currently trades at $59 per share, 6% below the level seen in March 2021, and it has room for growth, in our view.","og_url":"https:\/\/ifintechworld.com\/?p=65981","og_site_name":"iFintechWorld","article_published_time":"2023-09-27T13:20:05+00:00","article_modified_time":"2023-09-27T13:20:08+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/09\/1695820806_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=65981#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=65981"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80?","datePublished":"2023-09-27T13:20:05+00:00","dateModified":"2023-09-27T13:20:08+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=65981"},"wordCount":821,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Markets"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=65981#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=65981","url":"https:\/\/ifintechworld.com\/?p=65981","name":"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80? | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-09-27T13:20:05+00:00","dateModified":"2023-09-27T13:20:08+00:00","description":"Bristol Myers Squibb stock (NYSE: BMY) currently trades at $59 per share, 6% below the level seen in March 2021, and it has room for growth, in our view.","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=65981#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=65981"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=65981#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level Of $80?"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/65981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65981"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/65981\/revisions"}],"predecessor-version":[{"id":65983,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/65981\/revisions\/65983"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/65982"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}